iCAD (NASDAQ:ICAD) Earns Sell Rating from Analysts at Wall Street Zen

Wall Street Zen assumed coverage on shares of iCAD (NASDAQ:ICAD - Free Report) in a report issued on Tuesday. The brokerage issued a sell rating on the technology company's stock.

A number of other brokerages also recently issued reports on ICAD. Laidlaw restated a "hold" rating on shares of iCAD in a research report on Thursday, April 17th. BTIG Research downgraded iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th. Finally, Craig Hallum lowered iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th.

iCAD Stock Performance

NASDAQ:ICAD traded down $0.01 during trading hours on Tuesday, reaching $3.73. The stock had a trading volume of 274,795 shares, compared to its average volume of 407,299. The stock has a market capitalization of $102.37 million, a PE ratio of -28.69 and a beta of 1.35. iCAD has a 52 week low of $1.18 and a 52 week high of $4.02. The company has a 50 day moving average price of $2.84 and a two-hundred day moving average price of $2.47.

iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. The company had revenue of $4.87 million for the quarter, compared to analysts' expectations of $4.54 million. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.

Hedge Funds Weigh In On iCAD

Several hedge funds have recently added to or reduced their stakes in ICAD. Jane Street Group LLC bought a new stake in iCAD in the first quarter worth about $180,000. Goldman Sachs Group Inc. purchased a new stake in shares of iCAD in the first quarter worth approximately $44,000. Parkman Healthcare Partners LLC bought a new stake in shares of iCAD during the 1st quarter worth approximately $1,610,000. Cubist Systematic Strategies LLC bought a new stake in shares of iCAD during the 1st quarter worth approximately $71,000. Finally, Ethos Financial Group LLC purchased a new position in iCAD during the 1st quarter valued at $82,000. 24.61% of the stock is currently owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.